News

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...
Glucagon-like-peptide-1 agonists like Ozempic have become extremely popular for weight loss. In fact, about 1 in 8 Americans have taken a GLP-1 drug at some point in their life, according to KFF ...
An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 ...
About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...
Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...